# DeLLphi-300 (NCT03319940)

> Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03319940
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Amgen
- Conditions: Small Cell Lung Carcinoma
- Interventions: Tarlatamab; Pembrolizumab; CRS Mitigation Strategies
- Enrollment: 269
- Primary outcome: Number of participants with dose limiting toxicities (DLT) for all indications
- Primary outcome: Number of participants with treatment-emergent adverse events (AEs) for all indications
- Primary outcome: Number of participants with treatment-related AEs for all indications
- Primary outcome: Number of participants with clinically significant changes in vital signs for all indications
- Primary outcome: Number of participants with significant changes in electrocardiogram (ECG) for all indications
- Primary outcome: Number of participants with significant changes in physical examinations for all indications
- Primary outcome: Number of participants with significant changes in clinical laboratory tests for all indications

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 17
- YouTube: 8
- Podcasts: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=dellphi-300-nct03319940

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03319940", "email": "<work email>"}; the inbox owner confirms by the emailed link.